By Anika Milian, Esq., Co-Founding Partner, B&M Law Group, PLLC · November 18, 2026

The federal allowance to prescribe controlled substances by video, with no in-person visit, is scheduled to end on December 31, 2026. As of November 13, we found no fifth extension and no final special-registration rule published. If your clinic prescribes testosterone or phentermine by telehealth, you need a December plan now, not a January scramble.

This does not mean the allowance will definitely lapse. It means you should not count on an extension that has not been issued.

If you searched "DEA telemedicine deadline December 31, 2026" or "can I still prescribe testosterone by telehealth in Florida," this article is for you.

What the DEA telemedicine deadline December 31, 2026 actually is

Federal law (the Ryan Haight Act, 21 U.S.C. 829(e)) generally requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance over the internet. During the COVID-19 public health emergency, the DEA (Drug Enforcement Administration) allowed prescribers to skip that visit and use real-time audio-video instead.

The DEA has extended that allowance several times. The current extension is set to run through December 31, 2026.

Two drugs matter most to wellness and weight-loss clinics:

  • Testosterone is a Schedule III controlled substance.
  • Phentermine is a Schedule IV controlled substance.

Other controlled medications, such as ketamine, some stimulants and benzodiazepines, are affected the same way.

Why it works this way

Congress wrote the in-person rule to slow down online "pill mill" prescribing. The DEA's pandemic flexibilities were meant to be temporary, and the agency has said it wants a permanent framework.

That framework is a proposed "special registration" for telemedicine prescribers. The rule is not final. Its reference number is RIN 1117-AB40, and as of mid-November it was reported to be under review at the White House Office of Management and Budget (OMB).

So the situation is a deadline with no confirmed replacement. Medical groups, including the Alliance for Connected Care (November 2) and AAHD (November 3 to 5), have written to the DEA asking for more time. A request is not a decision.

Did anything change in 2026?

Yes, and mostly in the direction of uncertainty.

  • The current extension runs only through December 31, 2026.
  • No fifth extension had been published as of November 13.
  • No final special-registration rule had been published as of that date.

Things can move fast in late December. Check the DEA Diversion Control Division website and the Federal Register before you finalize your plan, and have your attorney confirm the status the week of December 15.

Florida's own telehealth law, section 456.47, Florida Statutes, also applies. It requires telehealth providers to meet the same standard of care as an in-person visit and sets its own limits on prescribing certain controlled substances by telehealth. Federal and state rules both have to be satisfied.

What your clinic needs to do before December 31

  1. Map your patients. Pull a list of every patient who receives testosterone, phentermine or any other controlled substance and has never had an in-person evaluation with your clinic. Sort them by next refill date.
  2. Schedule in-person visits first for the earliest refills. Book visits now, while calendars are open. Document the exam, history, vitals and the medical reason for the prescription.
  3. Check your medical director and every prescriber. Confirm each has an active Florida license and an active DEA registration. Confirm the DEA registration address and state coverage match how and where they prescribe.
  4. Review the telehealth and medical-director agreements. Confirm who is responsible for patient exams, prescribing, and record-keeping, and whether the agreement addresses a change in federal rules.
  5. Check E-FORCSE. Florida requires prescribers to consult the prescription drug monitoring database, E-FORCSE (section 893.055, Florida Statutes), before prescribing controlled substances. Document it every time.
  6. Tell patients early. Send a plain-language notice now. Explain that an in-person visit may be required, what it involves, and what happens to refills if the visit does not occur.
  7. Update consent forms and protocols. Your telehealth consent, intake forms and written protocols should match what you will actually do in January.

Signs your telehealth setup may be at risk

  • "Most of my testosterone patients are fully remote. I have never met them."
  • "Our weight-loss program is video-only from intake to refill."
  • "The medical director signs off, but I'm not sure which states their DEA registration covers."
  • "We use a third-party telehealth platform, so I assumed they handle compliance."
  • "Our consent form just says telehealth is available. It says nothing about in-person visits."
  • "We don't keep a record of the E-FORCSE check."
  • "Our medical-director agreement was signed years ago and nobody has read it since."

If any of these sound familiar, start with the patient map.

What can happen if you get it wrong

Prescribing a controlled substance without a valid practitioner-patient relationship can create exposure at the federal and state levels. Possible consequences include DEA action against a prescriber's registration, Florida Department of Health or Board of Medicine discipline, and claims from patients or payers.

The clinic can also face risk. In Florida, a medical director, a management company and the owners may each have responsibilities depending on how the agreements and ownership are structured. That is a good reason to review the contracts now, not after a problem.

Outcomes depend on the facts. Nothing here predicts what the DEA will do on January 1.

How to fix it: a quick checklist

  • Export a list of all controlled-substance patients and flag those with no in-person visit on file.
  • Book in-person visits for the soonest refills first.
  • Confirm each prescriber's Florida license and DEA registration before December 15.
  • Review the medical-director agreement and any telehealth platform contract.
  • Update consent forms, intake forms and written protocols.
  • Send a patient notice in English and Spanish.
  • Document every E-FORCSE check.
  • Prepare two plans: one if the DEA extends, one if it does not.
  • Recheck the DEA and Federal Register websites the week of December 15 and again December 29.

For related compliance topics, see our articles on APRN Botox supervision in Florida and the HHS peptide policy and medspa compliance.

FAQ

Will the DEA extend telemedicine flexibilities again after December 31, 2026?

We do not know. As of November 13, no fifth extension had been published, and groups have asked for one. Plan for both outcomes.

Can I still prescribe testosterone by telehealth in Florida after December 31?

Federal law generally requires at least one in-person medical evaluation first, unless an exception or a new DEA rule applies. Florida's telehealth law also applies. Confirm your situation with an attorney.

Is phentermine affected by the DEA telemedicine deadline?

Yes. Phentermine is a Schedule IV controlled substance, so the in-person evaluation rule applies if the flexibility ends.

Do I need an in-person visit for every refill?

Generally the federal rule is about the initial in-person medical evaluation, not every follow-up. Details and exceptions matter, so have your attorney review your protocol.

What happens to my phentermine patients I have only seen by video?

They will likely need an in-person visit if the federal flexibility ends. Identify them now and schedule their appointments early.

Who is responsible for compliance if my clinic uses a medical director?

Responsibility depends on the agreements and the structure of the practice. Review who prescribes, who examines patients, and who keeps records.

Talk to a Florida health care business attorney

B&M Law Group advises wellness clinics, medspas and weight-loss practices throughout Florida, in English and Spanish. We review telehealth and medical-director agreements, patient consent forms, and compliance plans for changes like this one. To plan before December 31, book a consultation.


Sources: AAHD: DEA telemedicine prescribing flexibilities · MedGrid MSO: DEA telemedicine flexibilities end December 31, 2026 · 21 U.S.C. 829 · Section 456.47, Florida Statutes · Section 893.055, Florida Statutes · DEA Diversion Control Division